Credit Suisse’s Protalix BioTherapeutics PLX Stock Holding History

Credit Suisse’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-31,974	Closed	-$43K	–	4639
2021 Q3	$43K	Sell	31,974 -33,951	-51%	-$51.6K	﹤0.01%	4352
2021 Q2	$126K	Buy	65,925 +55,925	+559%	+$192K	﹤0.01%	4347
2021 Q1	$45K	Buy	+10,000	New	+$46.6K	﹤0.01%	4232
2020 Q3	–	Sell	-10,000	Closed	-$38K	–	4103
2020 Q2	$38K	Buy	+10,000	New	+$34.2K	﹤0.01%	3889

Other funds holding PLX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Credit Suisse's PLX Position: Q4 2021 in Review

Credit Suisse sold out of Protalix BioTherapeutics (PLX) in Q4 2021, closing a stake of 31,974 shares — an estimated $43K sold.

Credit Suisse first reported a position in PLX in Q2 2020 and held it in 4 quarters. The position peaked at $126K in Q2 2021. 31 funds tracked by Wall St. Rank hold PLX as of Q4 2021.

Credit Suisse reported no remaining Protalix BioTherapeutics position as of Q4 2021 after selling out during the quarter.
Credit Suisse sold 31,974 Protalix BioTherapeutics shares in Q4 2021, an estimated $43K.
Credit Suisse first reported a position in Protalix BioTherapeutics in Q2 2020 and held it in 4 quarters.
Credit Suisse's Protalix BioTherapeutics position peaked at $126K in Q2 2021.
31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2021.

Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.